SlideShare uma empresa Scribd logo
1 de 39
Ovarian stimulation
Prof. Aboubakr Elnashar
Benha university, Egypt
ABOUBAKR ELNASHAR
CONTENTS
1.TYPES OF OVARIAN STIMULATION
2.TYPES OF ANOVULATION
3.HYPOGONADOTROPHIC HYPOESTROGENIC,
TYPE I
4.NORMOGONADOTROPHIC NORMOESTROGENIC,
TYPE II
5.HYPERGONADOTROPHIC HYPOESTROGENIC,
TYPE III
6.HYPERPROLACTINAEMIA, TYPE IV
ABOUBAKR ELNASHAR
TYPES OF OVARIAN STIMULATION
Controlled
ovarian
stimulation
Super
ovulation
Induction of
ovulation
Anovulatory or ovulatoryAnovulatoryPatient
Multiple> oneOne mature
follicle
Objective
IVFIUI
Unexp inf
Example
Down regulation
Stimulation
Prevent premature
LH surge
StimulationStimulationMethod
ABOUBAKR ELNASHAR
TYPES OF ANOVULATION
% Type Hormonal profile
5-10%
WHO type I
(Hypogonadotropic
Hypoestrogenic)
E2
FSH
75-80%
WHO type II
Normogenadotrophic
Normoestrogenic
Normal E2
Normal FSH
10-20%
WHO type III
(Hypergonadotropic
Hypoestrogenic)
E2
FSH
5-10%
WHO type IV
(Hyperprolactinemia) prolactin
WHO Scientific group, Geneva 1976, Report 514, Rowe et al, 1993ABOUBAKR ELNASHAR
Amenorrhea or severe oligomenorrhea
FSH & LH: low
Prolactin: normal
I. HYPOGONADOTROPHIC
HYPOESTROGENIC
TYPE I
ABOUBAKR ELNASHAR
1. Reverse the life style factors:
Increase wt if BMI <19
When the metabolic state is normalized reflected
by a normal BMI (>20 kg/m2), a regular menstrual
cycle will be restored in the majority of patients.
(Stafford, 2005)
Moderating exercise if high levels of exercise.
Treat stress
CC:
not effective
ABOUBAKR ELNASHAR
2. Gonadotrphins with LH activity or
Pulsatile GnRH (pump)
3. luteal support
hCG or progesterone from time of ovulation induction
until sufficient hCG production by trophoblast
cells is necessary.
(Beckers et al., 2006)
ABOUBAKR ELNASHAR
II. NORMOGONADOTROPHIC
NORMOESTROGENIC
TYPE II
PCOS
2 of 3 (Noterdam definition,2003):
•U/S PCO
•Hyperandrogenism (Clinical or Laboratory)
•Irregular or absent ovulation
ABOUBAKR ELNASHAR
Life style modification
Letrozole or CC
Obese &overweight
Normal weight &No weight loss & No ovulation
Laparoscopic ovarian drilling (LOD)Gonadotropins (FSH)
No ovulation after 3 cycles.
No pregnancy after 6 cycles.
No pregnancy
after 6 cycles.
No pregnancy after spontaneous,
Clomiphene, FSH ovulation
Assisted reproductive technology (IVF/ICSI)
Other surgical indication
Difficult follow up
Less aggressive
No desire for
surgery
Add metformin
IGT &IR
ABOUBAKR ELNASHAR
WHO, 2016
ABOUBAKR ELNASHAR
1.Weight reduction
 The treatment of obesity includes:
 Lifestyle modifications.
 Pharmacological treatment.
 Bariatric surgery.
1st -line therapy in obese PCOS patients seeking pregnancy.
Wt loss of 5% :restore reproductive function in PCOS.
(The Thessaloniki ESHRE/ASRM workshop, 2008)
ABOUBAKR ELNASHAR
1. Lifestyle modifications
Include:
1.Dietary modification:
2.Exercise:
3.Behavioral modification:
 Moderate-intensity aerobic activity (30 min & 5 days ).
 Vigorous-intensity aerobic activity (20 min & 3 days ).
 Resistance training (2 days).
 Hypocaloric diet (500–1,000 kcal/day reduction) .
 Rich in fiber, fruits, and vegetables.
 Calories: 50 % carbohydrates ,30 % fat and 20 % proteins.
 Correction of abnormal eating behaviors .
 Daily tracking of food intake and physical activity.
 Modify the patient’s environment to reduce stimuli leading to food
intake.
ABOUBAKR ELNASHAR
2. Pharmacological treatment
 Anti-obesity drugs (Orlistat - Sibutramine –Rimonabant )
Inhibition of gastric and pancreatic lipase .
120 mg t.d.s during or within 1 h of a fat meal.
 Mechanism of action:
 Dose:
 Comparison of orlistat with metformin:
 significant reduction in total testosterone, cholesterol and triglycerides
with orlistat, but ovulation rate was higher in metformin group.
(Ghandi et al., 2011)
Orlistat
 Fatty stool, headache, abdominal pain and back pain.
 It increases the anticoagulant effect of warfarin.
 Side effects:
ABOUBAKR ELNASHAR
3.Bariatric surgery
 Bariatric surgery includes:
 Gastric bypass.
 Sleeve gastrectomy.
 Gastric banding.
2nd -line treatment in obese PCOS (BMI ≥35 kg/m2) who are
anovulatory after lifestyle management at least for 6 months.
(Australian evidence-based guidelines for the management of PCOS)
ABOUBAKR ELNASHAR
2.Insulin sensitizers
Insulin-sensitizing drugs include:
 Biguanides (Metformin).
 Thiazolidinediones (Pioglitazone, Rosiglitazone, and Troglitazone).
Metformin
 enhances insulin sensitivity through :
 Liver: inhibition of glucose production.
 Peripheral tissue: increases glucose uptake and utilization in muscle
 Dose:
 Mechanism of action :
should not be used as 1st choice or as an adjuvant to CC.
restricted in patients with glucose intolerance.
(The Thessaloniki ESHRE/ASRM workshop, 2008)
Immediate release metformin: begin with 500 mg at dinner for 3–4 days,
and then increasing by 500 mg every 3–4 days up to a maximal dosage of
1000 mg twice daily.
Immediate release: 500, 850, and 1000 mg
Extended release: 1000 and 2000 mg
ABOUBAKR ELNASHAR
 Results:
1. improved PR but there is no evidence that it improves LBR (used
alone or in combination with CC).
(Cochrane review 2012)
2.Addition of metformin to CC improved ovulation in CC resistant
patients with insulin resistance and hyperandrogenism.
(Systematic review 2006)
3.It increases pregnancy and live birth rate, and reduces the
cancellation rate in PCOS treated with Gnt for ovulation induction.
(Palomba et al., 2014)
 Side effects:
 Gastrointestinal distress
 Lactic acidosis
ABOUBAKR ELNASHAR
2. Oral anti-estrogens
1. Clomiphene citrate
 binds to estrogen receptors in hypothalamus and pituitary gland:
release of hypothalamus from negative feedback effect of
estradiol: increasing production of endogenous Gnt from the
pituitary gland.
 Mechanism of action:
 Dose:
 50-150 mg for 5 days starting on 2nd to 5th day of cycle.
 Duration of Treatment:
 A course of 6 ovulatory cycles is sufficient as:
 75% of the pregnancies occur in the first 3 cycles.
 Pregnancies are rare after 6 ovulatory cycles.
ABOUBAKR ELNASHAR
 Results :
 Ovulation rate: 75% and PR: 35- 40%.
 The large gap between ovulation and pregnancy is due to anti-
estrogenic effects on endometrium and cervical mucus.
 Monitoring:
Objective evidence of ovulation is key to successful treatment.
1. Urinary ovulation kits: detect midcycle LH surge.
2. TVS: sudden collapse of the preovulatory follicle: increase in cul-de-
sac fluid volume
3. Mid-luteal progesterone: 3 ng/ml.
 Failure:
 CC treatment failure is divided into two groups:
1. CC-resistance: failure of ovulation after 150 mg of CC for at least
3 cycles.
2. CC- failure: failure to achieve pregnancy after 6-12 cycles despite
ovulation.
ABOUBAKR ELNASHAR
 Adjuvant treatments to CC:
1. Pre-treatment with COC: in cycle before taking CC increased ovulation
rates and PR. (Cochrane review , 2009)
2. Addition of metformin: improved ovulation in CC resistant patients with
insulin resistance and hyperandrogenism. (systematic review , 2006)
3. Addition of dexamethasone: (high dose 2 mg, short course 3-12 D of
the cycle): no adverse anti-estrogenic effect on endometrium and higher
ovulation and PR. (Elnashar et al., 2006)
4. Addition of coenzyme Q10 : improves ovulation and PR .
(El Refaeey et al., 2014)
 Side effects of CC:
 Mood swings :64%
 Hot flashes: 10%
 Visual disturbances: <2%
 Less specific side effects: breast tenderness, pelvic discomfort.
ABOUBAKR ELNASHAR
 Dose:
2. Tamoxifen
20–40 mg daily for 5 days .
 Results:
 Tamoxifen and CC are equally effective in inducing ovulation.
(Meta-analysis , Steiner et al., 2005)
 Combination of tamoxifen and CC improved ovulation and PR than CC
alone .
(Ghafourzadeh et al., 2004)
ABOUBAKR ELNASHAR
 Mechanism of action:
3. Aromatase inhibitors (AIs)
 At the central level: inhibiting of aromatase enzyme: release of
hypothalamus from the negative feedback effect of estrogen: increasing
production of endogenous Gnt from the pituitary gland.
 At the peripheral level: inhibition of aromatase enzyme: accumulation
of androgens which augment follicular FSH receptor expression and
stimulate IGF-1 which may act with FSH to promote folliculogenesis.
Aromatase inhibitors work both centrally (hypothalamus and pituitary) and
peripherally (ovaries)
ABOUBAKR ELNASHAR
 Result of AIs:
 Letrozole improves live birth and PR compared to CC .
 No evidence of difference in CPR between letrozole and LOD.
 No evidence of difference in CPR between
 letrozole and anastrozole.
 5 day and 10 day of letrozole.
 5 mg and 7.5 mg of letrozole.
 No evidence of difference in OHSS rate when letrozole was compared
with placebo , CC, LOD, and anastrozole.
(Cochrane review 2014)
 Letrozole might be associated with a higher risk of congenital
cardiac and bone malformations in newborns: Not proved
(ASRM meeting, 2005)
 Safety of AIs:
ABOUBAKR ELNASHAR
4. Gonadotropins
The main reasons for use of Gnt as 2nd line:
 Lack of an oral formulation.
 Expensive
 Serious side effects (multiple pregnancy and OHSS(
 Close monitoring with ultrasound.
2nd line treatment after CC resistance/failure
(The Thessaloniki ESHRE/ASRM workshop)
ABOUBAKR ELNASHAR
 Gonadotropin Preparations
• 3 main preparations: FSH, LH & HCG
• 2 types
I. Urinary
1. HMG
2. Highly purified HMG
3. Purified FSH
4. Highly purified FSH
5. Urinary HCG
II. Recombinant
1. Rec FSH
2. Rec HCG
3. Rec LH
ABOUBAKR ELNASHAR
Preparation Trade name Route U.pr FSH LH Price Company
HMG Menogon,
Pergonal,
Humegon,
IM 95% 75 75 66 Ferring
Serono
Organon
H.P.HMG Merional
Menopur
SC <5% 75 75 66
118
Ferring
Purified FSH Metrodine IM <5% 75
Urofillotropin
<0.1 Serono
H.P.FSH Fostimon
Bravelle
Metrodine HP
SC,
IM
<5% 75
Urofillotropin
<0.001 55
70
Ibsa
Ferring
Serono
HCG Pregnyl
Profasi
IM 95% Organon
Serono
H.P.HCG Choriomon SC,
IM
<5% 70 Ibsa
I. Urinary Gonadotropins in Egypt
ABOUBAKR ELNASHAR
II. Recombinant Gonadotropins
Preparation Trade name Route U.pr FSH LH company
1. FSH Gonal-f (follitropin)
Gonal-f FbM Pen
Puregon (follitropin)
Puregon pen
SC, IM
SC, IM
SC,IM
SC, Im
-
-
-
-
75,150
300,450,900
50,100
300,600
-
-
-
-
Serono
Serono
Organon
Organon
2. HCG Ovitrelle
Choriogonadotropin
SC - Serono
3. LH Luveris
lutotropin
SC - Serono
ABOUBAKR ELNASHAR
CHOICE OF GONADOTROPINS
No difference in outcome
between ovarian stimulation with hMG preparations or
urinary derived FSH, in studies using the long protocol of
GnRH desensitization.
(MA: Agrawal et al. 2000)
No significant clinical differences
between hMG and rFSH.
(Nugent et al., Cochrane Data base Syst Rev 2000; van Wely et al, 2003)
hMG, uFSH, and r-FSH:
equally effective for achieving pregnancy in PCOS.
(Al-lnany et al.,2005)
 Rec FSH make no difference to the incidence of OHSS.
The particular FSH formulation used for ovarian stimulation
does not affect the incidence of OHSS.
(SOGC, (I)
ABOUBAKR ELNASHAR
 Gonadotropin regimens:
3. Conventional step-up dose:
 Start with 150 IU of hMG.
 Increase by 50% every 3-5 days until an ovarian response .
 No longer recommended in PCOS ( high OHSS).
150 225
300
450
50-75 IU
14 days 7 days
1. Chronic low dose step-up:
 Start with 50 – 75 IU/day for 14 days.
 Increase by 25–37.5 every 7 days until follicular development is observed
 Maintained until follicular selection is achieved.
 Recommended in PCOS (low OHSS).
2. Low dose step up:
 Start with 75 IU/d for 5-7 d
 Increase by 100%
 Mono-ovulation: 69%
 MP: 5.7%
 OHSS: 0.14%
(Homburg & Howles, 1999)
5 days
3 days
3 days
ABOUBAKR ELNASHAR
 Monitoring:
 Serial E2 measurements.
 TVS: to reduce the risk of OHSS and multiple pregnancy.
 Risks:
 Multiple pregnancy :
depends on the number of large mature follicles.
 OHSS:
 The higher risk of OHSS in PCOS {large cohort of FSH sensitive
small antral follicles}
Cycle cancellation by withholding hCG administration and postponing
intercourse when:
 >4 follicles more than 14 mm (U.K. guidelines ), or > 3 follicles > 16 mm
 Serum E2 concentration > 2000 pg/ml (ASRM , 2008)
ABOUBAKR ELNASHAR
4. Laparoscopic ovarian drilling
 Mechanism of action:
2nd line treatment in CC-resistant PCOS patients, being as effective as
Gnt treatment.
(The Thessaloniki ESHRE/ASRM workshop, 2008)
1.Opening of the subcapsular cysts: release of androgen containing
follicular fluid. ( Daniell and Miller 1989)
2.Decreased LH and increased FSH after LOD (normalization of
FSH/LH ratio).
(Gadir et al., 1992)
 Number of punctures and amount of thermal energy:
 4 punctures, each for 4 seconds at a power 40 W, delivering 640
Joules/ovary
( Armar et al., 1993 )
 Adjusted thermal dose (60 J/cm3 of ovarian tissue): better ovulation
and
PR compared with fixed-puncture dosage (600 J/ovary ).
(Zakherah et al., 2011) ABOUBAKR ELNASHAR
 Efficacy :
 Ovulation rate: 30 to 90 %
 PR: 50 to 80 % within 1 year.
 Unilateral vs bilateral drilling:
 ULOD is effective as BLOD .
 ULOD: decreasing adhesion.
(Roy et al., 2009)
 Prediction of success:
 Marked obesity ,marked hyperandrogenism and/or longer duration
of infertility: resistant to LOD.
 LH levels >10 IU/L: higher pregnancy rates.
(Amer et al., 2004 )
ABOUBAKR ELNASHAR
 Comparison of LOD with other ovulatory drugs:
 No evidence of a difference in rates of LBR ,CPR, or
miscarriage rate between LOD and other medical treatments.
 LBR is low after LOD when compared with CC+ metformin.
 A significant reduction in multiple PR after LOD.
(Cochrane review 2012)
 Complications
1.Intra-operative:
Avulsion of utero-ovarian ligament-Bleeding from punctures
2.Long-term:
 Adhesion formation: high and their extent was not affected by the
number of punctures.
(Mercorio et al .2008)
 Decreased ovarian reserve: No evidence
Most of the changes in the ovarian reserve markers are due to
normalization of ovarian function rather than reduction of
ovarian reserve.
(Api , 2009)
ABOUBAKR ELNASHAR
III. HYPERGONADOTROPHIC
HYPOESTROGENIC
Type III
< 40 yr, 2ndry amenorrhea
Repeated FSH > 20 IU/L
Causes
1. Idiopathic.
2. Genetic.
3. Autoimmune
3. Viral/bacterial infection
4. Pelvic surgery, chemotherapy
5. Galactosemia
ABOUBAKR ELNASHAR
1. Oral contraceptive suppression of gonadotrpins
followed by discontinuation
to allow a rebound in gonadotropins & ovarian
function.
2. GnRHa suppression of gonadotropins secretion
followed by high dose gonadotropin injection
3. Glucocorticoids suppression of immune system.
Non of these tts has demonstrated efficacy in RCT
ABOUBAKR ELNASHAR
IV. HYPERPROLACTINAEMIA
Type IV
I. Idiopathic
Dopamine agonist (anxiety, pregnancy).
Stop during pregnancy
II. Microadenoma
Dopamine agonist (anxiety, pregnancy).
Stop after 2-3 yr.
Surgery (rapid growth).
III. Macroadenoma
Dopamine agonist: long term
Surgery
(No response, suprasellar extension, pregnancy).ABOUBAKR ELNASHAR
In order to induce fertility
1. Maintain the effective PRL lowering dose for
10–12 months
{it takes time to reestablish ovulatory cycles and half of the pregnancies
occur after the first 6 months of therapy}.
2. Monitor ovulation by measurements of plasma
progesterone.
3. If ovulation does not occur despite the
normalized PRL: CC .
ABOUBAKR ELNASHAR
Dopaminergic treatments
1st choice tt for both
idiopathic hyperprolactinemia
prolactinomas.
Dopamine receptors:
D1 and D2 subtypes
Binding of dopamine agonists to dopamine D2
receptors on the surface of lactotrophs: reduces adenyl
cyclase activity and inhibits prolactin secretion.
 3 dopamine agonist
ABOUBAKR ELNASHAR
Crosignani et al, 2012
ABOUBAKR ELNASHAR
Parlodel
lactodel
Bromocriptin
Dostinox
Cabergoumoun
Cabergolin
Norplac75 ugmQuinagolide
DoperginLisuride
You can get this lecture from:
1.My scientific page on Face book:
Aboubakr Elnashar Lectures.
https://www.facebook.com/groups/2
27744884091351/
2.Slide share web site
3.elnashar53@hotmail.com
4.My clinic althwara st. mansura
ABOUBAKR ELNASHAR

Mais conteúdo relacionado

Mais procurados

Controlled ovarian stimulation in IVF
Controlled ovarian stimulation in IVFControlled ovarian stimulation in IVF
Controlled ovarian stimulation in IVFAboubakr Elnashar
 
ENDOMETRIAL PREPARATION IN FROZEN EMBRYO TRANSFER CYCLES
ENDOMETRIAL PREPARATION IN FROZEN EMBRYO TRANSFER CYCLESENDOMETRIAL PREPARATION IN FROZEN EMBRYO TRANSFER CYCLES
ENDOMETRIAL PREPARATION IN FROZEN EMBRYO TRANSFER CYCLESAboubakr Elnashar
 
Recent advances in stimulation protocols
Recent advances in stimulation protocolsRecent advances in stimulation protocols
Recent advances in stimulation protocolsSandro Esteves
 
Indivisualization of Ovulation Induction - Dr Dhorepatil Bharati
Indivisualization of Ovulation Induction - Dr Dhorepatil BharatiIndivisualization of Ovulation Induction - Dr Dhorepatil Bharati
Indivisualization of Ovulation Induction - Dr Dhorepatil BharatiBharati Dhorepatil
 
Immunological issues in recurrent implant failure
Immunological issues in recurrent implant failureImmunological issues in recurrent implant failure
Immunological issues in recurrent implant failureArunSharma10
 
Ovulation Stimulation Protocols for IUI - Dr Dhorepatil Bharati
Ovulation Stimulation Protocols for IUI - Dr Dhorepatil BharatiOvulation Stimulation Protocols for IUI - Dr Dhorepatil Bharati
Ovulation Stimulation Protocols for IUI - Dr Dhorepatil BharatiBharati Dhorepatil
 
Use of LH in IVF and IUI
Use of LH in IVF and IUIUse of LH in IVF and IUI
Use of LH in IVF and IUISandro Esteves
 
Optimal endometrial preparation for frozen embryo transfer cycles
Optimal endometrial preparation for frozen embryo transfer cyclesOptimal endometrial preparation for frozen embryo transfer cycles
Optimal endometrial preparation for frozen embryo transfer cyclesnermine amin
 
MANAGEMENT OF POOR RESPONDERS IN IVF BY DR SHASHWAT JANI
MANAGEMENT OF POOR RESPONDERS  IN IVF BY DR SHASHWAT JANIMANAGEMENT OF POOR RESPONDERS  IN IVF BY DR SHASHWAT JANI
MANAGEMENT OF POOR RESPONDERS IN IVF BY DR SHASHWAT JANIDR SHASHWAT JANI
 
GnRH Antagonists in Controlled Ovarian Stimulation
GnRH Antagonists in Controlled Ovarian StimulationGnRH Antagonists in Controlled Ovarian Stimulation
GnRH Antagonists in Controlled Ovarian StimulationSandro Esteves
 
Monitoring ART cycle Aboubakr Elnashar
Monitoring ART cycle Aboubakr ElnasharMonitoring ART cycle Aboubakr Elnashar
Monitoring ART cycle Aboubakr ElnasharAboubakr Elnashar
 
NICE Guidelines 2013, in relation to IUI & IVF Dr. Jyoti Agarwal,Dr. Sharda J...
NICE Guidelines 2013, in relation to IUI & IVF Dr. Jyoti Agarwal,Dr. Sharda J...NICE Guidelines 2013, in relation to IUI & IVF Dr. Jyoti Agarwal,Dr. Sharda J...
NICE Guidelines 2013, in relation to IUI & IVF Dr. Jyoti Agarwal,Dr. Sharda J...Lifecare Centre
 
Factors affecting success of embryo transfer
Factors affecting success of embryo transferFactors affecting success of embryo transfer
Factors affecting success of embryo transferAboubakr Elnashar
 

Mais procurados (20)

Controlled ovarian stimulation in IVF
Controlled ovarian stimulation in IVFControlled ovarian stimulation in IVF
Controlled ovarian stimulation in IVF
 
ENDOMETRIAL PREPARATION IN FROZEN EMBRYO TRANSFER CYCLES
ENDOMETRIAL PREPARATION IN FROZEN EMBRYO TRANSFER CYCLESENDOMETRIAL PREPARATION IN FROZEN EMBRYO TRANSFER CYCLES
ENDOMETRIAL PREPARATION IN FROZEN EMBRYO TRANSFER CYCLES
 
Recent advances in stimulation protocols
Recent advances in stimulation protocolsRecent advances in stimulation protocols
Recent advances in stimulation protocols
 
EMPTY FOLLICLE SYNDROME
EMPTY FOLLICLE SYNDROMEEMPTY FOLLICLE SYNDROME
EMPTY FOLLICLE SYNDROME
 
Indivisualization of Ovulation Induction - Dr Dhorepatil Bharati
Indivisualization of Ovulation Induction - Dr Dhorepatil BharatiIndivisualization of Ovulation Induction - Dr Dhorepatil Bharati
Indivisualization of Ovulation Induction - Dr Dhorepatil Bharati
 
GnRH antagonists
GnRH antagonistsGnRH antagonists
GnRH antagonists
 
Immunological issues in recurrent implant failure
Immunological issues in recurrent implant failureImmunological issues in recurrent implant failure
Immunological issues in recurrent implant failure
 
Optimizing IUI Outcome
Optimizing IUI OutcomeOptimizing IUI Outcome
Optimizing IUI Outcome
 
Ovulation Stimulation Protocols for IUI - Dr Dhorepatil Bharati
Ovulation Stimulation Protocols for IUI - Dr Dhorepatil BharatiOvulation Stimulation Protocols for IUI - Dr Dhorepatil Bharati
Ovulation Stimulation Protocols for IUI - Dr Dhorepatil Bharati
 
Use of LH in IVF and IUI
Use of LH in IVF and IUIUse of LH in IVF and IUI
Use of LH in IVF and IUI
 
Tests for ovarian reserve
Tests for ovarian reserveTests for ovarian reserve
Tests for ovarian reserve
 
Optimal endometrial preparation for frozen embryo transfer cycles
Optimal endometrial preparation for frozen embryo transfer cyclesOptimal endometrial preparation for frozen embryo transfer cycles
Optimal endometrial preparation for frozen embryo transfer cycles
 
MANAGEMENT OF POOR RESPONDERS IN IVF BY DR SHASHWAT JANI
MANAGEMENT OF POOR RESPONDERS  IN IVF BY DR SHASHWAT JANIMANAGEMENT OF POOR RESPONDERS  IN IVF BY DR SHASHWAT JANI
MANAGEMENT OF POOR RESPONDERS IN IVF BY DR SHASHWAT JANI
 
Luteal Phase Support
 Luteal Phase Support Luteal Phase Support
Luteal Phase Support
 
GnRH Antagonists in Controlled Ovarian Stimulation
GnRH Antagonists in Controlled Ovarian StimulationGnRH Antagonists in Controlled Ovarian Stimulation
GnRH Antagonists in Controlled Ovarian Stimulation
 
Monitoring ART cycle Aboubakr Elnashar
Monitoring ART cycle Aboubakr ElnasharMonitoring ART cycle Aboubakr Elnashar
Monitoring ART cycle Aboubakr Elnashar
 
Treatment of decreased ovarian reserve
Treatment of decreased ovarian reserveTreatment of decreased ovarian reserve
Treatment of decreased ovarian reserve
 
Ivf in pcos
Ivf in pcosIvf in pcos
Ivf in pcos
 
NICE Guidelines 2013, in relation to IUI & IVF Dr. Jyoti Agarwal,Dr. Sharda J...
NICE Guidelines 2013, in relation to IUI & IVF Dr. Jyoti Agarwal,Dr. Sharda J...NICE Guidelines 2013, in relation to IUI & IVF Dr. Jyoti Agarwal,Dr. Sharda J...
NICE Guidelines 2013, in relation to IUI & IVF Dr. Jyoti Agarwal,Dr. Sharda J...
 
Factors affecting success of embryo transfer
Factors affecting success of embryo transferFactors affecting success of embryo transfer
Factors affecting success of embryo transfer
 

Semelhante a Ovarian stimulation

Obesity, SLE, Thyroid disease and ICSI
Obesity, SLE, Thyroid  disease   and ICSIObesity, SLE, Thyroid  disease   and ICSI
Obesity, SLE, Thyroid disease and ICSIAboubakr Elnashar
 
Clomiphene citrate adjunctives & alternatives
Clomiphene citrate  adjunctives & alternatives Clomiphene citrate  adjunctives & alternatives
Clomiphene citrate adjunctives & alternatives Aboubakr Elnashar
 
Controlled Ovarian Hyperstimulation With IUI
Controlled Ovarian Hyperstimulation With IUIControlled Ovarian Hyperstimulation With IUI
Controlled Ovarian Hyperstimulation With IUIBharati Dhorepatil
 
ART: Management of associated conditions
ART: Management of  associated conditionsART: Management of  associated conditions
ART: Management of associated conditionsAboubakr Elnashar
 
Infertility treatment related to PCOS
Infertility treatment related to PCOSInfertility treatment related to PCOS
Infertility treatment related to PCOSAboubakr Elnashar
 
Recurrent miscarriage RCOG, 2011 Up to date, 2013
Recurrent miscarriage RCOG, 2011 Up to date, 2013Recurrent miscarriage RCOG, 2011 Up to date, 2013
Recurrent miscarriage RCOG, 2011 Up to date, 2013Aboubakr Elnashar
 
Ovulation induction
Ovulation inductionOvulation induction
Ovulation inductionsunitafeme
 
Management of INFERTILITY in PCOD Difficulties & Solutions Made Easy , Dr....
Management of INFERTILITY in PCOD Difficulties & SolutionsMade Easy , Dr....Management of INFERTILITY in PCOD Difficulties & SolutionsMade Easy , Dr....
Management of INFERTILITY in PCOD Difficulties & Solutions Made Easy , Dr....Lifecare Centre
 
Stimulation protocol in ART: should we tailor it on AMH level?
Stimulation protocol in ART: should we tailor it on AMH level?Stimulation protocol in ART: should we tailor it on AMH level?
Stimulation protocol in ART: should we tailor it on AMH level?DrRokeyaBegum
 
Role of progestogens in obstetrics and gynecology
Role of progestogens in obstetrics and gynecologyRole of progestogens in obstetrics and gynecology
Role of progestogens in obstetrics and gynecologyAhmad Saber
 
Gonadotrpin ovarian stimulation
Gonadotrpin ovarian stimulationGonadotrpin ovarian stimulation
Gonadotrpin ovarian stimulationAboubakr Elnashar
 
Adjuvants in por (1)
Adjuvants in por (1)Adjuvants in por (1)
Adjuvants in por (1)rupalibassi
 
Uses of aromatase inhibitors in gynecology
Uses of   aromatase inhibitors   in gynecologyUses of   aromatase inhibitors   in gynecology
Uses of aromatase inhibitors in gynecologyAboubakr Elnashar
 
Role of GnRH agonist in benign gynaecological disorders
Role of GnRH agonist in benign gynaecological disordersRole of GnRH agonist in benign gynaecological disorders
Role of GnRH agonist in benign gynaecological disordersAboubakr Elnashar
 
OHSS: Prediction and prevention in non IVF cycles
OHSS:  Prediction and prevention in  non IVF cyclesOHSS:  Prediction and prevention in  non IVF cycles
OHSS: Prediction and prevention in non IVF cyclesAboubakr Elnashar
 
Progesterone in clinical practice
Progesterone in clinical practiceProgesterone in clinical practice
Progesterone in clinical practiceAboubakr Elnashar
 
24.复件 Family Panning2008
24.复件 Family Panning200824.复件 Family Panning2008
24.复件 Family Panning2008Deep Deep
 
Therapeutic uses of Progestagen in infertility and IVF
Therapeutic uses of  Progestagen  in infertility and IVF Therapeutic uses of  Progestagen  in infertility and IVF
Therapeutic uses of Progestagen in infertility and IVF Aboubakr Elnashar
 
HORMONAL CONTRACEPTIVES
HORMONAL CONTRACEPTIVESHORMONAL CONTRACEPTIVES
HORMONAL CONTRACEPTIVESsharonsheregar
 

Semelhante a Ovarian stimulation (20)

Obesity, SLE, Thyroid disease and ICSI
Obesity, SLE, Thyroid  disease   and ICSIObesity, SLE, Thyroid  disease   and ICSI
Obesity, SLE, Thyroid disease and ICSI
 
Clomiphene citrate adjunctives & alternatives
Clomiphene citrate  adjunctives & alternatives Clomiphene citrate  adjunctives & alternatives
Clomiphene citrate adjunctives & alternatives
 
Controlled Ovarian Hyperstimulation With IUI
Controlled Ovarian Hyperstimulation With IUIControlled Ovarian Hyperstimulation With IUI
Controlled Ovarian Hyperstimulation With IUI
 
ART: Management of associated conditions
ART: Management of  associated conditionsART: Management of  associated conditions
ART: Management of associated conditions
 
Infertility treatment related to PCOS
Infertility treatment related to PCOSInfertility treatment related to PCOS
Infertility treatment related to PCOS
 
Recurrent miscarriage RCOG, 2011 Up to date, 2013
Recurrent miscarriage RCOG, 2011 Up to date, 2013Recurrent miscarriage RCOG, 2011 Up to date, 2013
Recurrent miscarriage RCOG, 2011 Up to date, 2013
 
Ovulation induction
Ovulation inductionOvulation induction
Ovulation induction
 
Management of INFERTILITY in PCOD Difficulties & Solutions Made Easy , Dr....
Management of INFERTILITY in PCOD Difficulties & SolutionsMade Easy , Dr....Management of INFERTILITY in PCOD Difficulties & SolutionsMade Easy , Dr....
Management of INFERTILITY in PCOD Difficulties & Solutions Made Easy , Dr....
 
Stimulation protocol in ART: should we tailor it on AMH level?
Stimulation protocol in ART: should we tailor it on AMH level?Stimulation protocol in ART: should we tailor it on AMH level?
Stimulation protocol in ART: should we tailor it on AMH level?
 
Role of progestogens in obstetrics and gynecology
Role of progestogens in obstetrics and gynecologyRole of progestogens in obstetrics and gynecology
Role of progestogens in obstetrics and gynecology
 
Gonadotrpin ovarian stimulation
Gonadotrpin ovarian stimulationGonadotrpin ovarian stimulation
Gonadotrpin ovarian stimulation
 
Adjuvants in por (1)
Adjuvants in por (1)Adjuvants in por (1)
Adjuvants in por (1)
 
Uses of aromatase inhibitors in gynecology
Uses of   aromatase inhibitors   in gynecologyUses of   aromatase inhibitors   in gynecology
Uses of aromatase inhibitors in gynecology
 
Role of GnRH agonist in benign gynaecological disorders
Role of GnRH agonist in benign gynaecological disordersRole of GnRH agonist in benign gynaecological disorders
Role of GnRH agonist in benign gynaecological disorders
 
OHSS: Prediction and prevention in non IVF cycles
OHSS:  Prediction and prevention in  non IVF cyclesOHSS:  Prediction and prevention in  non IVF cycles
OHSS: Prediction and prevention in non IVF cycles
 
Progesterone in clinical practice
Progesterone in clinical practiceProgesterone in clinical practice
Progesterone in clinical practice
 
Hormonal contraceptives
Hormonal contraceptivesHormonal contraceptives
Hormonal contraceptives
 
24.复件 Family Panning2008
24.复件 Family Panning200824.复件 Family Panning2008
24.复件 Family Panning2008
 
Therapeutic uses of Progestagen in infertility and IVF
Therapeutic uses of  Progestagen  in infertility and IVF Therapeutic uses of  Progestagen  in infertility and IVF
Therapeutic uses of Progestagen in infertility and IVF
 
HORMONAL CONTRACEPTIVES
HORMONAL CONTRACEPTIVESHORMONAL CONTRACEPTIVES
HORMONAL CONTRACEPTIVES
 

Mais de Aboubakr Elnashar

WHAT IS NEW IN ESHRE 2022 AND FIGO 2022 FOR GENERAL GYNAECOLOGIST
WHAT IS NEW IN ESHRE 2022 AND FIGO 2022 FOR GENERAL GYNAECOLOGISTWHAT IS NEW IN ESHRE 2022 AND FIGO 2022 FOR GENERAL GYNAECOLOGIST
WHAT IS NEW IN ESHRE 2022 AND FIGO 2022 FOR GENERAL GYNAECOLOGISTAboubakr Elnashar
 
Adenomyosis associated infertility
Adenomyosis associated  infertilityAdenomyosis associated  infertility
Adenomyosis associated infertilityAboubakr Elnashar
 
Endometriosis associated infertility: ESHRE2022
Endometriosis associated infertility: ESHRE2022Endometriosis associated infertility: ESHRE2022
Endometriosis associated infertility: ESHRE2022Aboubakr Elnashar
 
Aesthetic gynecology controversy
Aesthetic gynecology controversyAesthetic gynecology controversy
Aesthetic gynecology controversyAboubakr Elnashar
 
Hormonal assay in clinical gyn
Hormonal assay in clinical gynHormonal assay in clinical gyn
Hormonal assay in clinical gynAboubakr Elnashar
 
Unnecessary investigations in reproductive medicine
Unnecessary investigations in reproductive medicineUnnecessary investigations in reproductive medicine
Unnecessary investigations in reproductive medicineAboubakr Elnashar
 
Individualisation of controlled ovarian stimulation
Individualisation of controlled ovarian stimulationIndividualisation of controlled ovarian stimulation
Individualisation of controlled ovarian stimulationAboubakr Elnashar
 
THE MANAGEMENT OF SEVERE PET/ECLAMPSIA
THE MANAGEMENT OF SEVERE PET/ECLAMPSIA THE MANAGEMENT OF SEVERE PET/ECLAMPSIA
THE MANAGEMENT OF SEVERE PET/ECLAMPSIA Aboubakr Elnashar
 
cesarean birth: procedural aspects: NICE2021
cesarean birth: procedural aspects: NICE2021  cesarean birth: procedural aspects: NICE2021
cesarean birth: procedural aspects: NICE2021 Aboubakr Elnashar
 
Management of pregnancy of unknown location
Management of pregnancy of unknown locationManagement of pregnancy of unknown location
Management of pregnancy of unknown locationAboubakr Elnashar
 
COVID 19 infection and pregnancy RCOG2021
COVID 19 infection and pregnancy RCOG2021COVID 19 infection and pregnancy RCOG2021
COVID 19 infection and pregnancy RCOG2021Aboubakr Elnashar
 

Mais de Aboubakr Elnashar (20)

WHAT IS NEW IN ESHRE 2022 AND FIGO 2022 FOR GENERAL GYNAECOLOGIST
WHAT IS NEW IN ESHRE 2022 AND FIGO 2022 FOR GENERAL GYNAECOLOGISTWHAT IS NEW IN ESHRE 2022 AND FIGO 2022 FOR GENERAL GYNAECOLOGIST
WHAT IS NEW IN ESHRE 2022 AND FIGO 2022 FOR GENERAL GYNAECOLOGIST
 
hepatitis B.pdf
hepatitis B.pdfhepatitis B.pdf
hepatitis B.pdf
 
hepatitis c2022.pdf
hepatitis c2022.pdfhepatitis c2022.pdf
hepatitis c2022.pdf
 
Adenomyosis associated infertility
Adenomyosis associated  infertilityAdenomyosis associated  infertility
Adenomyosis associated infertility
 
Endometriosis associated infertility: ESHRE2022
Endometriosis associated infertility: ESHRE2022Endometriosis associated infertility: ESHRE2022
Endometriosis associated infertility: ESHRE2022
 
Adenxal mass guidelines2020
Adenxal mass guidelines2020Adenxal mass guidelines2020
Adenxal mass guidelines2020
 
Aesthetic gynecology controversy
Aesthetic gynecology controversyAesthetic gynecology controversy
Aesthetic gynecology controversy
 
Hormonal assay in clinical gyn
Hormonal assay in clinical gynHormonal assay in clinical gyn
Hormonal assay in clinical gyn
 
FIRST TRIMESTER ANC OF IVF
FIRST TRIMESTER ANC OF IVFFIRST TRIMESTER ANC OF IVF
FIRST TRIMESTER ANC OF IVF
 
Unnecessary investigations in reproductive medicine
Unnecessary investigations in reproductive medicineUnnecessary investigations in reproductive medicine
Unnecessary investigations in reproductive medicine
 
Infertility prevention
Infertility prevention Infertility prevention
Infertility prevention
 
Individualisation of controlled ovarian stimulation
Individualisation of controlled ovarian stimulationIndividualisation of controlled ovarian stimulation
Individualisation of controlled ovarian stimulation
 
Female infertility
Female infertility Female infertility
Female infertility
 
Maternal near miss
Maternal near missMaternal near miss
Maternal near miss
 
THE MANAGEMENT OF SEVERE PET/ECLAMPSIA
THE MANAGEMENT OF SEVERE PET/ECLAMPSIA THE MANAGEMENT OF SEVERE PET/ECLAMPSIA
THE MANAGEMENT OF SEVERE PET/ECLAMPSIA
 
cesarean birth: procedural aspects: NICE2021
cesarean birth: procedural aspects: NICE2021  cesarean birth: procedural aspects: NICE2021
cesarean birth: procedural aspects: NICE2021
 
CAESAREAN SCAR DEFECT
CAESAREAN SCAR DEFECT  CAESAREAN SCAR DEFECT
CAESAREAN SCAR DEFECT
 
Management of pregnancy of unknown location
Management of pregnancy of unknown locationManagement of pregnancy of unknown location
Management of pregnancy of unknown location
 
Aerobic Vaginitis
Aerobic Vaginitis Aerobic Vaginitis
Aerobic Vaginitis
 
COVID 19 infection and pregnancy RCOG2021
COVID 19 infection and pregnancy RCOG2021COVID 19 infection and pregnancy RCOG2021
COVID 19 infection and pregnancy RCOG2021
 

Último

EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionkrishnareddy157915
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisSujoy Dasgupta
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfHongBiThi1
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)kishan singh tomar
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdfHongBiThi1
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.aarjukhadka22
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communicationskatiequigley33
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Vaikunthan Rajaratnam
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.pptRamDBawankar1
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE Mamatha Lakka
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptxWINCY THIRUMURUGAN
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...Sujoy Dasgupta
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfMedicoseAcademics
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologyDeepakDaniel9
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfHongBiThi1
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaSujoy Dasgupta
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.whalesdesign
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectiondrhanifmohdali
 

Último (20)

EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung function
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosis
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)
 
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communications
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdf
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacology
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
 
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissection
 

Ovarian stimulation

  • 1. Ovarian stimulation Prof. Aboubakr Elnashar Benha university, Egypt ABOUBAKR ELNASHAR
  • 2. CONTENTS 1.TYPES OF OVARIAN STIMULATION 2.TYPES OF ANOVULATION 3.HYPOGONADOTROPHIC HYPOESTROGENIC, TYPE I 4.NORMOGONADOTROPHIC NORMOESTROGENIC, TYPE II 5.HYPERGONADOTROPHIC HYPOESTROGENIC, TYPE III 6.HYPERPROLACTINAEMIA, TYPE IV ABOUBAKR ELNASHAR
  • 3. TYPES OF OVARIAN STIMULATION Controlled ovarian stimulation Super ovulation Induction of ovulation Anovulatory or ovulatoryAnovulatoryPatient Multiple> oneOne mature follicle Objective IVFIUI Unexp inf Example Down regulation Stimulation Prevent premature LH surge StimulationStimulationMethod ABOUBAKR ELNASHAR
  • 4. TYPES OF ANOVULATION % Type Hormonal profile 5-10% WHO type I (Hypogonadotropic Hypoestrogenic) E2 FSH 75-80% WHO type II Normogenadotrophic Normoestrogenic Normal E2 Normal FSH 10-20% WHO type III (Hypergonadotropic Hypoestrogenic) E2 FSH 5-10% WHO type IV (Hyperprolactinemia) prolactin WHO Scientific group, Geneva 1976, Report 514, Rowe et al, 1993ABOUBAKR ELNASHAR
  • 5. Amenorrhea or severe oligomenorrhea FSH & LH: low Prolactin: normal I. HYPOGONADOTROPHIC HYPOESTROGENIC TYPE I ABOUBAKR ELNASHAR
  • 6. 1. Reverse the life style factors: Increase wt if BMI <19 When the metabolic state is normalized reflected by a normal BMI (>20 kg/m2), a regular menstrual cycle will be restored in the majority of patients. (Stafford, 2005) Moderating exercise if high levels of exercise. Treat stress CC: not effective ABOUBAKR ELNASHAR
  • 7. 2. Gonadotrphins with LH activity or Pulsatile GnRH (pump) 3. luteal support hCG or progesterone from time of ovulation induction until sufficient hCG production by trophoblast cells is necessary. (Beckers et al., 2006) ABOUBAKR ELNASHAR
  • 8. II. NORMOGONADOTROPHIC NORMOESTROGENIC TYPE II PCOS 2 of 3 (Noterdam definition,2003): •U/S PCO •Hyperandrogenism (Clinical or Laboratory) •Irregular or absent ovulation ABOUBAKR ELNASHAR
  • 9. Life style modification Letrozole or CC Obese &overweight Normal weight &No weight loss & No ovulation Laparoscopic ovarian drilling (LOD)Gonadotropins (FSH) No ovulation after 3 cycles. No pregnancy after 6 cycles. No pregnancy after 6 cycles. No pregnancy after spontaneous, Clomiphene, FSH ovulation Assisted reproductive technology (IVF/ICSI) Other surgical indication Difficult follow up Less aggressive No desire for surgery Add metformin IGT &IR ABOUBAKR ELNASHAR
  • 11. 1.Weight reduction  The treatment of obesity includes:  Lifestyle modifications.  Pharmacological treatment.  Bariatric surgery. 1st -line therapy in obese PCOS patients seeking pregnancy. Wt loss of 5% :restore reproductive function in PCOS. (The Thessaloniki ESHRE/ASRM workshop, 2008) ABOUBAKR ELNASHAR
  • 12. 1. Lifestyle modifications Include: 1.Dietary modification: 2.Exercise: 3.Behavioral modification:  Moderate-intensity aerobic activity (30 min & 5 days ).  Vigorous-intensity aerobic activity (20 min & 3 days ).  Resistance training (2 days).  Hypocaloric diet (500–1,000 kcal/day reduction) .  Rich in fiber, fruits, and vegetables.  Calories: 50 % carbohydrates ,30 % fat and 20 % proteins.  Correction of abnormal eating behaviors .  Daily tracking of food intake and physical activity.  Modify the patient’s environment to reduce stimuli leading to food intake. ABOUBAKR ELNASHAR
  • 13. 2. Pharmacological treatment  Anti-obesity drugs (Orlistat - Sibutramine –Rimonabant ) Inhibition of gastric and pancreatic lipase . 120 mg t.d.s during or within 1 h of a fat meal.  Mechanism of action:  Dose:  Comparison of orlistat with metformin:  significant reduction in total testosterone, cholesterol and triglycerides with orlistat, but ovulation rate was higher in metformin group. (Ghandi et al., 2011) Orlistat  Fatty stool, headache, abdominal pain and back pain.  It increases the anticoagulant effect of warfarin.  Side effects: ABOUBAKR ELNASHAR
  • 14. 3.Bariatric surgery  Bariatric surgery includes:  Gastric bypass.  Sleeve gastrectomy.  Gastric banding. 2nd -line treatment in obese PCOS (BMI ≥35 kg/m2) who are anovulatory after lifestyle management at least for 6 months. (Australian evidence-based guidelines for the management of PCOS) ABOUBAKR ELNASHAR
  • 15. 2.Insulin sensitizers Insulin-sensitizing drugs include:  Biguanides (Metformin).  Thiazolidinediones (Pioglitazone, Rosiglitazone, and Troglitazone). Metformin  enhances insulin sensitivity through :  Liver: inhibition of glucose production.  Peripheral tissue: increases glucose uptake and utilization in muscle  Dose:  Mechanism of action : should not be used as 1st choice or as an adjuvant to CC. restricted in patients with glucose intolerance. (The Thessaloniki ESHRE/ASRM workshop, 2008) Immediate release metformin: begin with 500 mg at dinner for 3–4 days, and then increasing by 500 mg every 3–4 days up to a maximal dosage of 1000 mg twice daily. Immediate release: 500, 850, and 1000 mg Extended release: 1000 and 2000 mg ABOUBAKR ELNASHAR
  • 16.  Results: 1. improved PR but there is no evidence that it improves LBR (used alone or in combination with CC). (Cochrane review 2012) 2.Addition of metformin to CC improved ovulation in CC resistant patients with insulin resistance and hyperandrogenism. (Systematic review 2006) 3.It increases pregnancy and live birth rate, and reduces the cancellation rate in PCOS treated with Gnt for ovulation induction. (Palomba et al., 2014)  Side effects:  Gastrointestinal distress  Lactic acidosis ABOUBAKR ELNASHAR
  • 17. 2. Oral anti-estrogens 1. Clomiphene citrate  binds to estrogen receptors in hypothalamus and pituitary gland: release of hypothalamus from negative feedback effect of estradiol: increasing production of endogenous Gnt from the pituitary gland.  Mechanism of action:  Dose:  50-150 mg for 5 days starting on 2nd to 5th day of cycle.  Duration of Treatment:  A course of 6 ovulatory cycles is sufficient as:  75% of the pregnancies occur in the first 3 cycles.  Pregnancies are rare after 6 ovulatory cycles. ABOUBAKR ELNASHAR
  • 18.  Results :  Ovulation rate: 75% and PR: 35- 40%.  The large gap between ovulation and pregnancy is due to anti- estrogenic effects on endometrium and cervical mucus.  Monitoring: Objective evidence of ovulation is key to successful treatment. 1. Urinary ovulation kits: detect midcycle LH surge. 2. TVS: sudden collapse of the preovulatory follicle: increase in cul-de- sac fluid volume 3. Mid-luteal progesterone: 3 ng/ml.  Failure:  CC treatment failure is divided into two groups: 1. CC-resistance: failure of ovulation after 150 mg of CC for at least 3 cycles. 2. CC- failure: failure to achieve pregnancy after 6-12 cycles despite ovulation. ABOUBAKR ELNASHAR
  • 19.  Adjuvant treatments to CC: 1. Pre-treatment with COC: in cycle before taking CC increased ovulation rates and PR. (Cochrane review , 2009) 2. Addition of metformin: improved ovulation in CC resistant patients with insulin resistance and hyperandrogenism. (systematic review , 2006) 3. Addition of dexamethasone: (high dose 2 mg, short course 3-12 D of the cycle): no adverse anti-estrogenic effect on endometrium and higher ovulation and PR. (Elnashar et al., 2006) 4. Addition of coenzyme Q10 : improves ovulation and PR . (El Refaeey et al., 2014)  Side effects of CC:  Mood swings :64%  Hot flashes: 10%  Visual disturbances: <2%  Less specific side effects: breast tenderness, pelvic discomfort. ABOUBAKR ELNASHAR
  • 20.  Dose: 2. Tamoxifen 20–40 mg daily for 5 days .  Results:  Tamoxifen and CC are equally effective in inducing ovulation. (Meta-analysis , Steiner et al., 2005)  Combination of tamoxifen and CC improved ovulation and PR than CC alone . (Ghafourzadeh et al., 2004) ABOUBAKR ELNASHAR
  • 21.  Mechanism of action: 3. Aromatase inhibitors (AIs)  At the central level: inhibiting of aromatase enzyme: release of hypothalamus from the negative feedback effect of estrogen: increasing production of endogenous Gnt from the pituitary gland.  At the peripheral level: inhibition of aromatase enzyme: accumulation of androgens which augment follicular FSH receptor expression and stimulate IGF-1 which may act with FSH to promote folliculogenesis. Aromatase inhibitors work both centrally (hypothalamus and pituitary) and peripherally (ovaries) ABOUBAKR ELNASHAR
  • 22.  Result of AIs:  Letrozole improves live birth and PR compared to CC .  No evidence of difference in CPR between letrozole and LOD.  No evidence of difference in CPR between  letrozole and anastrozole.  5 day and 10 day of letrozole.  5 mg and 7.5 mg of letrozole.  No evidence of difference in OHSS rate when letrozole was compared with placebo , CC, LOD, and anastrozole. (Cochrane review 2014)  Letrozole might be associated with a higher risk of congenital cardiac and bone malformations in newborns: Not proved (ASRM meeting, 2005)  Safety of AIs: ABOUBAKR ELNASHAR
  • 23. 4. Gonadotropins The main reasons for use of Gnt as 2nd line:  Lack of an oral formulation.  Expensive  Serious side effects (multiple pregnancy and OHSS(  Close monitoring with ultrasound. 2nd line treatment after CC resistance/failure (The Thessaloniki ESHRE/ASRM workshop) ABOUBAKR ELNASHAR
  • 24.  Gonadotropin Preparations • 3 main preparations: FSH, LH & HCG • 2 types I. Urinary 1. HMG 2. Highly purified HMG 3. Purified FSH 4. Highly purified FSH 5. Urinary HCG II. Recombinant 1. Rec FSH 2. Rec HCG 3. Rec LH ABOUBAKR ELNASHAR
  • 25. Preparation Trade name Route U.pr FSH LH Price Company HMG Menogon, Pergonal, Humegon, IM 95% 75 75 66 Ferring Serono Organon H.P.HMG Merional Menopur SC <5% 75 75 66 118 Ferring Purified FSH Metrodine IM <5% 75 Urofillotropin <0.1 Serono H.P.FSH Fostimon Bravelle Metrodine HP SC, IM <5% 75 Urofillotropin <0.001 55 70 Ibsa Ferring Serono HCG Pregnyl Profasi IM 95% Organon Serono H.P.HCG Choriomon SC, IM <5% 70 Ibsa I. Urinary Gonadotropins in Egypt ABOUBAKR ELNASHAR
  • 26. II. Recombinant Gonadotropins Preparation Trade name Route U.pr FSH LH company 1. FSH Gonal-f (follitropin) Gonal-f FbM Pen Puregon (follitropin) Puregon pen SC, IM SC, IM SC,IM SC, Im - - - - 75,150 300,450,900 50,100 300,600 - - - - Serono Serono Organon Organon 2. HCG Ovitrelle Choriogonadotropin SC - Serono 3. LH Luveris lutotropin SC - Serono ABOUBAKR ELNASHAR
  • 27. CHOICE OF GONADOTROPINS No difference in outcome between ovarian stimulation with hMG preparations or urinary derived FSH, in studies using the long protocol of GnRH desensitization. (MA: Agrawal et al. 2000) No significant clinical differences between hMG and rFSH. (Nugent et al., Cochrane Data base Syst Rev 2000; van Wely et al, 2003) hMG, uFSH, and r-FSH: equally effective for achieving pregnancy in PCOS. (Al-lnany et al.,2005)  Rec FSH make no difference to the incidence of OHSS. The particular FSH formulation used for ovarian stimulation does not affect the incidence of OHSS. (SOGC, (I) ABOUBAKR ELNASHAR
  • 28.  Gonadotropin regimens: 3. Conventional step-up dose:  Start with 150 IU of hMG.  Increase by 50% every 3-5 days until an ovarian response .  No longer recommended in PCOS ( high OHSS). 150 225 300 450 50-75 IU 14 days 7 days 1. Chronic low dose step-up:  Start with 50 – 75 IU/day for 14 days.  Increase by 25–37.5 every 7 days until follicular development is observed  Maintained until follicular selection is achieved.  Recommended in PCOS (low OHSS). 2. Low dose step up:  Start with 75 IU/d for 5-7 d  Increase by 100%  Mono-ovulation: 69%  MP: 5.7%  OHSS: 0.14% (Homburg & Howles, 1999) 5 days 3 days 3 days ABOUBAKR ELNASHAR
  • 29.  Monitoring:  Serial E2 measurements.  TVS: to reduce the risk of OHSS and multiple pregnancy.  Risks:  Multiple pregnancy : depends on the number of large mature follicles.  OHSS:  The higher risk of OHSS in PCOS {large cohort of FSH sensitive small antral follicles} Cycle cancellation by withholding hCG administration and postponing intercourse when:  >4 follicles more than 14 mm (U.K. guidelines ), or > 3 follicles > 16 mm  Serum E2 concentration > 2000 pg/ml (ASRM , 2008) ABOUBAKR ELNASHAR
  • 30. 4. Laparoscopic ovarian drilling  Mechanism of action: 2nd line treatment in CC-resistant PCOS patients, being as effective as Gnt treatment. (The Thessaloniki ESHRE/ASRM workshop, 2008) 1.Opening of the subcapsular cysts: release of androgen containing follicular fluid. ( Daniell and Miller 1989) 2.Decreased LH and increased FSH after LOD (normalization of FSH/LH ratio). (Gadir et al., 1992)  Number of punctures and amount of thermal energy:  4 punctures, each for 4 seconds at a power 40 W, delivering 640 Joules/ovary ( Armar et al., 1993 )  Adjusted thermal dose (60 J/cm3 of ovarian tissue): better ovulation and PR compared with fixed-puncture dosage (600 J/ovary ). (Zakherah et al., 2011) ABOUBAKR ELNASHAR
  • 31.  Efficacy :  Ovulation rate: 30 to 90 %  PR: 50 to 80 % within 1 year.  Unilateral vs bilateral drilling:  ULOD is effective as BLOD .  ULOD: decreasing adhesion. (Roy et al., 2009)  Prediction of success:  Marked obesity ,marked hyperandrogenism and/or longer duration of infertility: resistant to LOD.  LH levels >10 IU/L: higher pregnancy rates. (Amer et al., 2004 ) ABOUBAKR ELNASHAR
  • 32.  Comparison of LOD with other ovulatory drugs:  No evidence of a difference in rates of LBR ,CPR, or miscarriage rate between LOD and other medical treatments.  LBR is low after LOD when compared with CC+ metformin.  A significant reduction in multiple PR after LOD. (Cochrane review 2012)  Complications 1.Intra-operative: Avulsion of utero-ovarian ligament-Bleeding from punctures 2.Long-term:  Adhesion formation: high and their extent was not affected by the number of punctures. (Mercorio et al .2008)  Decreased ovarian reserve: No evidence Most of the changes in the ovarian reserve markers are due to normalization of ovarian function rather than reduction of ovarian reserve. (Api , 2009) ABOUBAKR ELNASHAR
  • 33. III. HYPERGONADOTROPHIC HYPOESTROGENIC Type III < 40 yr, 2ndry amenorrhea Repeated FSH > 20 IU/L Causes 1. Idiopathic. 2. Genetic. 3. Autoimmune 3. Viral/bacterial infection 4. Pelvic surgery, chemotherapy 5. Galactosemia ABOUBAKR ELNASHAR
  • 34. 1. Oral contraceptive suppression of gonadotrpins followed by discontinuation to allow a rebound in gonadotropins & ovarian function. 2. GnRHa suppression of gonadotropins secretion followed by high dose gonadotropin injection 3. Glucocorticoids suppression of immune system. Non of these tts has demonstrated efficacy in RCT ABOUBAKR ELNASHAR
  • 35. IV. HYPERPROLACTINAEMIA Type IV I. Idiopathic Dopamine agonist (anxiety, pregnancy). Stop during pregnancy II. Microadenoma Dopamine agonist (anxiety, pregnancy). Stop after 2-3 yr. Surgery (rapid growth). III. Macroadenoma Dopamine agonist: long term Surgery (No response, suprasellar extension, pregnancy).ABOUBAKR ELNASHAR
  • 36. In order to induce fertility 1. Maintain the effective PRL lowering dose for 10–12 months {it takes time to reestablish ovulatory cycles and half of the pregnancies occur after the first 6 months of therapy}. 2. Monitor ovulation by measurements of plasma progesterone. 3. If ovulation does not occur despite the normalized PRL: CC . ABOUBAKR ELNASHAR
  • 37. Dopaminergic treatments 1st choice tt for both idiopathic hyperprolactinemia prolactinomas. Dopamine receptors: D1 and D2 subtypes Binding of dopamine agonists to dopamine D2 receptors on the surface of lactotrophs: reduces adenyl cyclase activity and inhibits prolactin secretion.  3 dopamine agonist ABOUBAKR ELNASHAR
  • 38. Crosignani et al, 2012 ABOUBAKR ELNASHAR Parlodel lactodel Bromocriptin Dostinox Cabergoumoun Cabergolin Norplac75 ugmQuinagolide DoperginLisuride
  • 39. You can get this lecture from: 1.My scientific page on Face book: Aboubakr Elnashar Lectures. https://www.facebook.com/groups/2 27744884091351/ 2.Slide share web site 3.elnashar53@hotmail.com 4.My clinic althwara st. mansura ABOUBAKR ELNASHAR